Evaluaion of tolerability and efficacy of Melatrance lightening cream for the treatment of melasma

Evaluaion of tolerability and efficacy of Melatrance lightening cream for the treatment of mild to moderate melasma

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT20190210042676N25

Enrollment

Registered

2022-07-07

Start date

2022-07-23

Completion date

Unknown

Last updated

2022-08-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Melasma. Chloasma

Interventions

Intervention group: Using Melatrance lightening cream(Contains Tranexamic acid, Carica papaya, Psidium guajava, saxifragaceae and Pisum sativum)produced by Knowledge-based company of Janus on patient

Eligibility

Sex/Gender

All

Age

18 Years to 50 Years

Inclusion criteria

Inclusion criteria: 18 - 50 years old men and women Cases of mild to moderate melasma (MGSC=1& 2) General health Signing the consent form for participation in the study

Exclusion criteria

Exclusion criteria: Documented allergies to components of cream Use of topical lightening products like AHA ,BHA and retinoid component within 21 days prior to the study Pregnancy or lactating

Design outcomes

Primary

Measure	Time frame
Modified melasma severity index. Timepoint: Before intervention, 6 weeks later and 12 weeks after intervention. Method of measurement: Using mMASI index.	—

Secondary

Measure	Time frame
Skin melanin content changes. Timepoint: Before intervention,6 and 12 weeks after using. Method of measurement: mexameter.;Size and amount of skin spots. Timepoint: Before intervention, 6 and 12 weeks after using. Method of measurement: Visio face.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAniseh Samadi

Tehran University of Medical Sciences

aniseh_samadi@yahoo.com+98 21 8896 0880

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026